MedTrace Logo

Predicting Cancer Risk With Digital and Molecular Markers

NCT06962670 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1250

Last updated 2025-05-08

No results posted yet for this study

Summary

The goal of this study is to identify new markers to predict the risk of developing cancer, primarily breast cancer. For this purpose, researchers will compare data obtained from cancer patients and healthy individuals. If characteristic differences are identified, e.g. in biomarkers, life style or family history, this may indicate a person's increased risk of developing cancer.

Conditions

Interventions

OTHER

Biomaterial collection

All subjects will be asked to provide biomaterial (blood or saliva) for bio marker screening and analysis. Additional biomaterial (breath, urin, stool) is optional.

OTHER

BayPass mobile application

All subjects will be asked to use the study-specific mobile application "BayPass" to complete questionnaires and provide results from screening examinations over a course of 12 months.

Sponsors & Collaborators

  • University of Erlangen-Nürnberg Medical School

    lead OTHER

Principal Investigators

  • Matthias W. Beckmann, Prof. Dr. med. · Head of Department of Obstetrics and Gynecology

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-09-14
Primary Completion
2025-09-30
Completion
2025-12-31

Countries

  • Germany

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06962670 on ClinicalTrials.gov